<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04341701</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2018/37</org_study_id>
    <nct_id>NCT04341701</nct_id>
  </id_info>
  <brief_title>Phenotype Identification Based on Multimodal MRI Analysis of Patients With Bronchial Obstructive Diseases</brief_title>
  <acronym>PIMABOD</acronym>
  <official_title>Phenotype Identification Based on Multimodal MRI Analysis of Patients With Bronchial Obstructive Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis is that pulmonary and cardiac proton MRI allows phenotyping of patients with&#xD;
      bronchial obstruction by cluster analysis based on quantitative multimodal imaging of&#xD;
      bronchi, pulmonary vessels, pulmonary parenchyma, right and left ventricular function,&#xD;
      myocardial fibrosis and pulmonary arterial pressure.&#xD;
&#xD;
      Such imaging will also offer the advantage of being non-irradiating and without contrast&#xD;
      products, which will ultimately allow CT to be replaced by MRI in the follow-up of bronchial&#xD;
      obstructive patients, thus avoiding the risks associated with repeated exposure to ionizing&#xD;
      radiation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bronchial obstructive diseases such as asthma and chronic obstructive pulmonary disease&#xD;
      (COPD) are very common and represent a major public health problem. The distinction between&#xD;
      these two diseases is sometimes difficult. In each of these diseases, several clinical&#xD;
      phenotypes or biological endotypes have been defined. For example, frequent exacerbating&#xD;
      patients and / or hypereosinophilic patients are present in both diseases. In the severe&#xD;
      states, cardiovascular comorbidities are the most frequent comorbidities and alter the&#xD;
      prognosis.&#xD;
&#xD;
      In these chronic obstructive patients, computed tomography (CT) allows a multimodal analysis&#xD;
      of the bronchial wall, the lung parenchyma and pulmonary vessels. CT also allows a score&#xD;
      analysis of coronary plaques. However, irradiation is significant and increases with repeated&#xD;
      examinations. CT does not allow a comprehensive analysis of cardiac function, or an estimate&#xD;
      of pulmonary artery pressure.&#xD;
&#xD;
      Magnetic Resonance Imaging (MRI) is a proton non-ionizing alternative to CT, in particular&#xD;
      when using 3D ultra-short echo-time (UTE) sequences. These 3D-UTE sequences decrease the&#xD;
      effects of magnetic susceptibility and provide morphological and morphometric information on&#xD;
      bronchi and lung comparable to those obtained by CT. Moreover, dedicated sequences add&#xD;
      functional information on bronchi. Heart MRI allows more analyses, such as right and left&#xD;
      ventricular systolic functions, an indirect estimate of pulmonary arterial pressure and the&#xD;
      amount of diffuse myocardial fibrosis.&#xD;
&#xD;
      Our project aims to identify morphological phenotypes through the pulmonary and heart MRI in&#xD;
      patients with obstructive lung disease&#xD;
&#xD;
      .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 5, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>diagnostic imaging pilot study, exploratory, prospective, multi-center</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the number of the clusters</measure>
    <time_frame>Day 30</time_frame>
    <description>Number of the clusters will be defined using principal component analysis and dendrogram, based on the multimodal lung and heart MRI analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the Quality of the clusters</measure>
    <time_frame>Day 30</time_frame>
    <description>Quality of the clusters will be defined using Dunn index and non-hierarchical analysis based on the multimodal lung and heart MRI analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of age</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of sexe</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of tobacco consumption</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of disease duration</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation score of SF-36 questionnaire</measure>
    <time_frame>Day 1</time_frame>
    <description>Determine the quality of life. SF36: 36-Item Short Form health survey Minimum = 0 and maximum = 100 Higher score means better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation with St Georges Quality of Life Questionnaire</measure>
    <time_frame>Day 30</time_frame>
    <description>Determine the quality of life. Minimum = 0 and maximum = 100 Higher score means worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of comorbidities</measure>
    <time_frame>Day 1</time_frame>
    <description>The presence of various comorbidities will be checked in a yes/No manner :&#xD;
rhinitis&#xD;
sinusitis&#xD;
nasal polyposis&#xD;
gastroesophageal reflux&#xD;
obstructive sleep apnea&#xD;
depression&#xD;
anxiety&#xD;
allery&#xD;
heart failure (Left or Right)&#xD;
hypertension&#xD;
myocardial infarction&#xD;
stroke&#xD;
arteriopathy&#xD;
arythmia&#xD;
diabetis&#xD;
dyslipidaemia&#xD;
obesity&#xD;
denutrition&#xD;
osteoporosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine of Forced Expiratory Volume in one sec (FEV-1) during spirometry before and after bronchodilator</measure>
    <time_frame>day 1</time_frame>
    <description>Assessment of FEV-1/FVC during spirometry before and after bronchodilator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine of Forced Vital Capacity (FVC) during spirometry before and after bronchodilator</measure>
    <time_frame>day 1</time_frame>
    <description>Assessment of FEV-1/FVC during spirometry before and after bronchodilator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine of slow Vital Capacity (VC) during spirometry before and after bronchodilator</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine of Total Lung Capacity (TLC) during spirometry before and after bronchodilator</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine of Functional Residual Capacity (FRC) during spirometry before and after bronchodilator</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine of Residual Volume (RV) during spirometry before and after bronchodilator</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine of Carbon monoxide transfer capacity (TLCO)</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the value of blood heamoglobin</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the value of blood eosinophils</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the value of blood C-reactive protein</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the value of blood B-type natriuretic peptide</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the value of blood total IgE at</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the value of blood total IgE</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Asthma Copd</condition>
  <arm_group>
    <arm_group_label>COPD</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>COPD according to GOLD 2019 but unrestricted to any level of bronchial reversibility established by the pulmonologist</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asthma</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>asthma according to GINA 2019 but without any smoking restriction</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>The procedure to study lung and heart MRI, performed on a 1.5T magnet (Siemens), without any injection or inhalation of contrast agent</description>
    <arm_group_label>Asthma</arm_group_label>
    <arm_group_label>COPD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Man or woman aged between 40 and 70 years.&#xD;
&#xD;
          -  Having benefited under the current care of spirometry showing FEV / FVC&#xD;
             pre-bronchodilation &lt;0.70 at steady state (i.e., without exacerbation from at least 4&#xD;
             weeks).&#xD;
&#xD;
          -  Having a diagnosis of asthma according to GINA 2019 without smoking restrictions or&#xD;
             COPD according to GOLD 2019 but unrestricted to any level of bronchial reversibility&#xD;
             to bronchodilator established by the pulmonologist.&#xD;
&#xD;
          -  On stable cardiopulmonary medications for at least 4 weeks&#xD;
&#xD;
          -  Having given his written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject deprived of liberty by judicial or administrative decision.&#xD;
&#xD;
          -  Major protected by law.&#xD;
&#xD;
          -  Subject not affiliated to a social security scheme, whether or not the beneficiary of&#xD;
             such a regime.&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Inability to complete the Questionnaire SF-36 and SGQLQ.&#xD;
&#xD;
          -  Subject in times of exclusion in relation to another protocol.&#xD;
&#xD;
          -  History of pulmonary fibrosis, primary pulmonary hypertension and cystic fibrosis.&#xD;
&#xD;
          -  History of lung resection (referred to oncological or volume reduction)&#xD;
&#xD;
          -  History of cancer except skin cancer (squamous and Basal) under 5 years&#xD;
&#xD;
          -  History of chest radiation&#xD;
&#xD;
          -  Pacemaker carrier subject or implantable defibrillator, intraocular metallic foreign&#xD;
             body, metal clip intracranial, heart valve prosthesis kind Starr-Edwards pre-6000, or&#xD;
             biomedical insulin pump type device, Neurostimulator or cochlear implant, Metal&#xD;
             patches.&#xD;
&#xD;
          -  Subject claustrophobic or unable to stay elongate during 30 minutes.&#xD;
&#xD;
          -  Subject with a waist circumference greater than 200 cm.&#xD;
&#xD;
          -  Occurrence of an exacerbation between the FE and MRI&#xD;
&#xD;
          -  Uninterpretable MRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick BERGER, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick BERGER, MD, PhD</last_name>
    <phone>+335 57 65 65 13</phone>
    <email>patrick.berger@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Virginie NIEL</last_name>
    <phone>+335 57 62 31 94</phone>
    <email>virginie.niel@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre hospitalier de la Côte Basque</name>
      <address>
        <city>Bayonne</city>
        <zip>64100</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Elise ABRAHAM, MD</last_name>
      <phone>+335 59 44 35 35</phone>
      <email>eabraham@ch-cotebasque.fr</email>
    </contact>
    <investigator>
      <last_name>Elise ABRAHAM, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Augustin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Annaig OZIER, MD</last_name>
      <phone>+335 56 24 21 79</phone>
      <email>ozierannaig@icloud.com</email>
    </contact>
    <investigator>
      <last_name>Annaig OZIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Médical Toki Eder</name>
      <address>
        <city>Cambo-les-Bains</city>
        <zip>64250</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Alain BERNADY, MD</last_name>
      <phone>+335 59 93 56 00</phone>
      <email>al.bernady@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Alain BERNADY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Le Cluzeau - CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Boris MELONI, MD</last_name>
      <phone>+335 55 05 68 81</phone>
      <email>boris.melloni@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Boris MELONI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de Pneumologie Bordeaux Rive droite</name>
      <address>
        <city>Lormont</city>
        <zip>33310</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Laurent FALQUE, MD</last_name>
      <phone>+335 56 32 80 58</phone>
      <email>laurent.falque@orange.fr</email>
    </contact>
    <investigator>
      <last_name>Laurent FALQUE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Haut-Lévêque - CHU de Bordeaux</name>
      <address>
        <city>Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Patrick BERGER, MD, PhD</last_name>
      <phone>+335 57 65 65 13</phone>
      <email>patrick.berger@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Virginie NIEL</last_name>
      <phone>+335 57 62 31 94</phone>
      <email>virginie.niel@chu-bordeaux.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Pierre-Olivier GIRODET, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick BERGER, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maéva ZYSMAN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 2, 2020</study_first_submitted>
  <study_first_submitted_qc>April 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2020</study_first_posted>
  <last_update_submitted>April 8, 2020</last_update_submitted>
  <last_update_submitted_qc>April 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MRI</keyword>
  <keyword>multimodal</keyword>
  <keyword>phenotypes</keyword>
  <keyword>lung</keyword>
  <keyword>heart</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

